NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Sponsor:

Pennsylvania State University

Sponsor Study ID:

NMTRC014

CTO #:

102520

NCT Number:

NCT02679144

Phase:

II

Protocol Type:

Prevention

Age Group:

Both

Disease Sites:

Brain and Nervous System

Study Objectives:

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)